1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 63629-1196
  5. Product Images: Simvastatin

Product Images Simvastatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Simvastatin NDC 63629-1196 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Footnote for Table 3 - Footnote for Table 3

Footnote for Table 3 - Footnote for Table 3

This text includes information on the results of a chemical assay, specifically for CYP3Ad inhibitors like ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone. It also notes that simvastatin acid is the p-hydroxyacid of simvastatin, and that the effect of grapefruit juice on simvastatin pharmacokinetics has not been fully studied. The text includes details on the administration of grapefruit juice and simvastatin for both single-strength and double-strength variations.*

Label - lbl636291196

Label - lbl636291196

This is a description of pharmaceutical tablets containing Simvastatin. Each tablet has a strength of 5mg and is recommended to be kept out of the reach of children. The tablets should be stored at a controlled room temperature between 20 to 25 degrees Celsius. The tablets should be dispensed in a light-resistant container with a child-resistant closure. The NDC number for these tablets is 63629-1196-1, and they come in a bottle containing 90 tablets.*

Figure 9 - simvastatin 10

Figure 9 - simvastatin 10

table2 - simvastatin 2

table2 - simvastatin 2

The table shows adverse reactions reported by patients treated with Simvastatin and those treated with a placebo. The reactions listed are those that affected 2% or more of patients taking Simvastatin and affecting more patients than the placebo. These reactions include various disorders across the body systems such as body swelling, abdominal pain, atrial fibrillation, constipation, diabetes mellitus, myalgia, headache, insomnia, eczema, and urinary tract infections.*

Structure - simvastatin 3

Structure - simvastatin 3

table 3 - simvastatin 4

table 3 - simvastatin 4

table 4 - simvastatin 5

table 4 - simvastatin 5

Figure 5 - simvastatin 6

Figure 5 - simvastatin 6

This appears to be a table of data related to a study on major vascular events and major coronary events in patients taking Simvastatin versus a placebo. It includes patient characteristics and instances of various diseases, as well as risk ratios. However, the data is not presented in a clear format and the exact details are difficult to decipher.*

Figure 6 - simvastatin 7

Figure 6 - simvastatin 7

Figure 7 - simvastatin 8

Figure 7 - simvastatin 8

The text is not-available.*

Figure 8 - simvastatin 9

Figure 8 - simvastatin 9

table 1 - table1

table 1 - table1

The text is a table containing a list of drug interactions that increase the risk of myopathy and rhabdomyolysis. Each interacting agent is followed by prescribing recommendations to minimize the risk of adverse reactions. Some of the drugs listed include strong CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and lomitapide. The use of grapefruit juice is to be avoided, and for Chinese patients, niacin is not recommended with simvastatin. The last line of the text is not readable.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.